During HZNP’s earnings call, Madhu Kumar of Goldman Sachs inquired whether the Inflation Reduction Act’s drug pricing provisions have altered corporate strategy regarding indication expansions on approved drugs and pipeline candidates.
During HZNP’s earnings call, Madhu Kumar of Goldman Sachs inquired whether the Inflation Reduction Act’s drug pricing provisions have altered corporate strategy regarding indication expansions on approved drugs and pipeline candidates.
